GRALHealthcare · Diagnostics & ResearchThe 10 Wall Street analysts covering GRAIL, Inc. hold a median 12-month price target of $150 — +4.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 4 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores GRAIL, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Volatility (11): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on GRAL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +4.3% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | $60 → $120 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $88 → $180 |
| 2 Oct 2026 | UBS | Maintains | Buy | — |
| 2 Oct 2026 | UBS | Maintains | Buy | $105 → $175 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | — |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $75 → $155 |
| 28 Sept 2026 | Canaccord Genuity | Maintains | Buy | — |
| 28 Sept 2026 | Canaccord Genuity | Maintains | Buy | $80 → $150 |
| 25 Sept 2026 | Mizuho | Maintains | Neutral | — |
| 25 Sept 2026 | Mizuho | Maintains | Neutral | $65 → $100 |
| 22 Sept 2026 | Baird | Maintains | Outperform | — |
| 22 Sept 2026 | Baird | Maintains | Outperform | $96 → $118 |
| 17 Sept 2026 | RBC Capital | Initiates | Sector Perform | $84 |
| 17 Sept 2026 | RBC Capital | Initiates | Sector Perform | — |
| 9 Sept 2026 | UBS | Initiates | Buy | $105 |
| 9 Sept 2026 | UBS | Initiates | Buy | — |
| 15 July 2026 | Mizuho | Maintains | Neutral | $58 → $65 |
| 15 July 2026 | Mizuho | Maintains | Neutral | — |
| 5 June 2026 | Goldman Sachs | Initiates | Neutral | $60 |
| 5 June 2026 | Goldman Sachs | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GRAL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, GRAIL, Inc. returned +78.2% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 6% of US stocks
Cheaper than 36% of US stocks
Cheaper than 88% of US stocks
Higher than 75% of US stocks
Higher than 64% of US stocks
Higher than 3% of US stocks
Higher than 9% of US stocks
Higher than 2% of US stocks
Higher than 33% of US stocks
Higher than 25% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
GRAIL, Inc. has a market value of $6.0B and an enterprise value of $5.2B.
Revenue in the twelve months to 30 June 2026: $165.3M. The latest quarter grew 25.7% year on year.
Net income over the same four quarters: −$391.6M, a −236.9% net margin.
Diluted earnings per share, trailing twelve months: $−9.75.
Free cash flow in the twelve months to 30 June 2026: −$296.2M.
Trailing P/E: −12.7×; forward P/E: −17.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
GRAIL, Inc. employs 910 people — $182K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own GRAIL, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of GRAIL, Inc.’s Q3 2026 earnings call.
Why it matters — The transcript provides GRAL watchers with the company’s remarks during its Q3 2026 earnings call.
GRAIL reported 4% revenue growth in the third quarter of 2026, as higher testing volumes were partly offset by lower prices. The company said it expects a U.S. regulatory decision on its Galleri cancer screening test by early in the first quarter of 2027.
Why it matters — The update highlights both recent revenue drivers and the expected timing of a regulatory decision for Galleri.
GRAIL shares fell late Wednesday after the company reported third-quarter sales below expectations.
Why it matters — The sales shortfall and share decline are relevant to GRAL watchers assessing the company’s latest results.
GRAIL reported third-quarter 2026 Galleri revenue of $37.3 million, up 14% year over year. Galleri test volume rose about 24% to more than 56,000, while year-to-date volume increased about 36% to more than 174,000; an FDA advisory committee voted in favor of approval of the test.
Why it matters — The results provide updates on Galleri's test volume and revenue growth, alongside an FDA advisory committee vote relevant to the test's approval process.
Zacks Investment Research said GRAIL's Q3 earnings should have benefited from rising adoption of its Galleri test, expanding digital health partnerships, and growing clinical evidence of cancer detection.
Why it matters — The item highlights Galleri adoption, partnerships, and clinical evidence as factors relevant to GRAIL's Q3 results.
The 10 Wall Street analysts covering GRAIL, Inc. have a median 12-month price target of $150, with estimates ranging from $74 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering GRAIL, Inc., 5 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GRAIL, Inc. 36 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, GRAIL, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +4.3% from the last close, and Ticker Nerd's factor model ranks GRAIL, Inc. 36 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering GRAIL, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRAL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $74 to $180 over the next 12 months.
GRAIL, Inc. returned +78.2% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services.
The most recent item we track (Seeking Alpha, 5 Nov 2026): "GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of GRAIL, Inc.’s Q3 2026 earnings call.
GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services. Its core offering is Galleri, a blood-based screening test designed to detect multiple cancer types before symptoms appear, supporting earlier clinical evaluation and diagnosis. The company uses next-generation sequencing, machine learning, software, and automation to analyze biological signals associated with cancer and deliver screening insights through laboratory and service workflows. GRAIL serves healthcare providers and patients in the United States and international markets, with its work centered on cancer screening, diagnostic support, and related laboratory services. Headquartered in Menlo Park, California, GRAIL plays a notable role in the expanding field of liquid biopsy and genomic diagnostics, where it contributes to efforts aimed at improving early cancer detection and broadening access to advanced screening technologies.
CEO Dr. Joshua J. Ofman M.D., M.S.H.S · 910 employees · United States · https://grail.com
